Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
japanese encephalitis vaccine (live, attenuated)
- Development stage
- Unknown
- Lead developer
- Chengdu Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The SA14-14-2 live-attenuated Japanese encephalitis virus vaccine is a safe and highly effective vaccine used for active immunization against Japanese encephalitis (JE). Developed by the Chengdu Institute of Biological Products (CDIBP) in China, the vaccine is prepared by propagating the attenuated SA14-14-2 strain of the Japanese encephalitis virus (JEV) in primary hamster kidney cell cultures. It is the first JE vaccine to be prequalified by the World Health Organization (WHO) for pediatric use. Administered subcutaneously, a single dose of the vaccine provides long-term protective immunity (at least five years) in endemic areas by eliciting robust neutralizing antibody and cell-mediated immune responses.
- Brand names
- CD.JEVAXRS.JEV
- Other names
- CD-JEVAXJapanese Encephalitis Vaccine Live (SA14-14-2)Japanese encephalitis vaccine, live, attenuatedLAJEVlive attenuated Japanese encephalitis vaccinelive-attenuated Japanese encephalitis virus vaccineRS-JEVSA14-14-2 live-attenuated Japanese encephalitis virus vaccineSA-14-14-2 live-attenuated Japanese encephalitis virus vaccineSA 14-14-2 live-attenuated Japanese encephalitis virus vaccine
Beyond the preview
Go deeper on japanese encephalitis vaccine (live, attenuated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on japanese encephalitis vaccine (live, attenuated).